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Background: Hepatitis C virus (HCV) genotype and subtype are related to disease progression and response to
antiviral therapy. Current HCV genotype and subtype distribution data, especially for genotypes 3 and 6, are limited
in China. Our purpose was to investigate the current HCV genotype and subtype distributions in chronic hepatitis C
patients in China.
Methods: Chronic hepatitis C patients (n = 1012) were enrolled, and demographic information and possible
transmission risk factors were collected. Serum samples were subjected to reverse-transcription polymerase chain
reaction, followed by direct DNA sequencing and phylogenetic analysis of the NS5B and core/E1 regions to
determine HCV genotypes/subtypes. The geographical distributions of HCV genotypes/subtypes were analyzed.
Demographic information and transmission risk factors were compared between different HCV genotypes/subtypes.
Results: Four genotypes and seven subtypes of HCV were detected in 970 patients. Subtypes 1b, 2a, 3a, 6a, 3b, 6n,
and 1a were detected at frequencies of 71.96 %, 19.90 %, 3.20 %, 2.16 %, 1.96 %, 0.41 %, and 0.41 %, respectively.
Genotypes 3 and 6 showed an increasingly wide geographic distribution over time. Patients with subtypes 1b and
2a were older than those with 3a, 3b, 6a, and 6n subtypes (p < 0.05 in all subtypes). More genotype 1 and 2
patients underwent blood transfusion than those with genotype 3 (all p < 0.05). More genotype 3 and 6 patients
had a history of intravenous drug use than those with genotypes 1 and 2 (all p < 0.05).
Conclusions: Though subtypes 1b and 2a are still the most prevalent HCV subtypes in China, genotype 3 and 6
HCV infections have already spread nationwide from southern and western China.
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Hepatitis C virus (HCV) is a leading cause of chronic liver
disease and presents a major threat to global public health.
Worldwide, more than 185 million people have been in-
fected [1], and these individuals face an increased risk of
developing liver cirrhosis and hepatocellular carcinoma.* Correspondence: zlyhmu@163.com; chengj0817@sina.cn
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creativecommons.org/publicdomain/zero/1.0/HCV can be classified into seven genotypes and at
least 67 confirmed subtypes, 20 provisionally assigned
subtypes, and 21 unassigned subtypes [2]. Genotypes 1,
2, and 3 are distributed globally. In contrast, genotypes
4, 5, and 6 are more concentrated to specific regions.
Genotype 4 and subtype 5a are mainly found in Middle
Eastern countries and the northern part of South Africa,
respectively. Genotype 6 is mainly found in China and
Southeast Asia, especially in the Hong Kong Special Ad-
ministrative Region of the People's Republic of China
(HKSAR), Thailand, and Vietnam [3, 4].distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 2 Geographical distributions of HCV subtypes of 1012
patients
Geographic origin n (%) HCV subtypes
1a 1b 2a 3a 3b 6a 6n NAa
Northeastern China 111(10.97) 0 71 37 0 1 1 0 1
Northern China 403(39.82) 1 270 90 13 7 3 0 19
Eastern China 275(27.17) 3 212 23 10 6 8 3 10
Central China 40(3.95) 0 31 8 0 0 0 0 1
Southern China 59(5.83) 0 36 9 4 1 9 0 0
Western China 124(12.25) 0 78 26 4 4 0 1 11
Total 1012(100) 4 698 193 31 19 21 4 42
aHCV RNA could not be amplified for genotyping
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A previous report indicated that subtypes 1b and 2a were
the dominant subtypes in China, although the incidences of
genotype 3 and 6 HCV infections were increasing [6].
Owing to the changing routes of transmission and increas-
ing global travel, the geographical and genetic diversity of
HCV is constantly changing. Recently, studies on HCV
genotype distribution in local regions and certain patients
populations were reported [7–10]. Yet nationwide HCV
genotype and subtype distribution data of chronic hepatitis
C patients is limited. We conducted this large-sample,
multi-centered study to investigate the status quo of HCV
genotype and subtype distribution in chronic hepatitis C
patients in China.
Results
Characteristics of the study population
Overall, 1012 chronic hepatitis C patients were enrolled
from 23 centers. Patients were located in 24 administrative
units from six different geographic regions throughout
China. Table 1 summarizes the demographic features and
geographic origins of all enrolled patients.
HCV sequence amplification, genotyping, and
phylogenetic analysis
Reliable nucleotide sequences of the NS5B and core/E1
region were obtained for 970 samples and used to con-
struct phylogenetic trees. The phylogenetic analysis of
both the NS5B and core/E1 regions revealed the pres-
ence of genotypes 1, 2, 3, and 6, while no genotype 4, 5,
or 7 strains were found in this study (Table 2).
HCV genotype 1 was the most prevalent, found in 702
(72.37 %) patients. The next most abundant genotypes were
2, 3, and 6, found in 193 (19.90 %), 50 (5.15 %), and 25Table 1 Demographic features and geographic origins of 1012






Median (range) 46 (12–99)
Mean ± SD 48.8 ± 14.7
Geographic origin, n (%)
Northeastern China 111 (10.97)
Northern China 403 (39.82)
Central China 40 (3.95)
Eastern China 275 (27.17)
Southern China 59 (5.83)
Western China 124 (12.25)(2.58 %) patients, respectively. Evaluations of subtype re-
vealed that the most common was 1b, accounting for
71.96 % (698/970) of cases, followed by 2a (19.90 %; 193/
970). Subtypes 3a, 6a, and 3b were identified in 31 (3.20 %),
21 (2.16 %), and 19 (1.96 %) patients, respectively. The least
frequent subtypes were 1a and 6n, with each accounting for
4 (0.41 %) specimens.
In phylogenetic analyses of the NS5B and core/E1 re-
gions, the sequences of each subtype were randomly dis-
tributed with other corresponding reference sequences
derived from the Los Alamos HCV database. No clear
geographical clustering of Chinese isolates in this study
was detected (Additional files 1, 2, 3, 4, 5, 6 and 7).Geographic distribution of HCV subtypes in China
Subtypes 1b and 2a were detected in all 6 geographic re-
gions. Subtype 3b was found in all geographic regions ex-
cept central China. Subtype 3a was found in 4 geographic
regions, but not in central or northeastern China. Subtype
6a was found in 4 geographic regions but not in central or
western China. Subtype 1a was isolated from patients in
eastern and northern China. Subtype 6n strains were iso-
lated from subjects from eastern and western China. All 7
subtypes were detected in eastern China. Other subtypes
were found in northern (subtype 6), southern and western
(subtype 5), and northeastern (subtype 4) China. Only 2
subtypes were detected in central China.Age versus subtype in the patient population
Age differences were observed for some HCV subtypes.
Patients infected with HCV subtype 1b (49.8 ± 15.0 years)
and 2a (51.2 ± 12.9 years) were older than those infected
with 3a (36.1 ± 9.8 years), 3b (37.0 ± 9.2 years), 6a (38.2 ±
12.1 years), and 6n (31.5 ± 10.3 years; p < 0.05 in each for
all pairwise comparisons of 1b and 2a with 3a, 3b, 6a, and
6n). There were no differences in the mean ages between
subtypes 1b and 2a (all p > 0.05). There was also no dif-
ference in the mean ages between patients with subtypes
3a, 3b, 6a, and 6n (p > 0.05 in all cases).
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A comparison of patients’ risk factors for HCV infec-
tion and the detected HCV subtypes are shown in
Table 3. A greater proportion of genotype 1 (p = 0.002)
and 2 (p = 0.011) patients underwent blood transfusion
compared to patients with genotype 3 infections. More
genotype 1 patients underwent surgery than those with
genotype 3 (p = 0.003). More genotype 2 patients un-
derwent invasive procedures than those with genotype 1
(p = 0.015). Invasive procedures were performed more fre-
quently in patients with genotype 2 and 3 infections com-
pared to genotype 6 (all p < 0.05). The history of IDU was
more prevalent in genotype 3 and 6 patients than in pa-
tients with genotypes 1 or 2 (all p < 0.05).
Family clustering of HCV was reported in 16 patients
with subtypes 1b (n = 13) and 2a (n = 3), although these
patients were all from different families. The mean age
was 50.1 ± 10.9 (range, 21–65) years and 37.50 % (6/16)
of the patients were female. They were from all geo-
graphic regions, except Southern China.
Discussion
Knowledge on HCV genotypes and subtypes is import-
ant for clinical management of chronic hepatitis C, since
discrete HCV genotypes respond differently to several
treatment regimens [11, 12]. Treatment with pegylated
interferon (IFN) and ribavirin is still the standard of care
for chronic hepatitis C patients in China. However, sev-
eral direct-acting antivirals (DAA) are in Phase III clin-
ical trials. Even in the context of IFN-free DAA therapy,
different HCV genotypes or subtypes can respond differ-
ently to the same DAA agent, leading to different resist-
ance profiles [13]. Thus, it is imperative to clarify the
current HCV genotype and subtype distribution in
chronic hepatitis C patients in China.
In 2005, Lu et al. reported the HCV genotype distribu-
tion in China; they found that genotypes 1b and 2a were
the dominant subtypes and genotypes 3 and 6 were lim-
ited to southern and southwestern China [6]. Since then,
many studies of genotype/subtype distribution in local re-
gions and specific populations have been reported [7–10].
Particularly recently, Li et al. reported the epidemiology of
hepatitis C virus infection in highly endemic HBV areas
[7]. Gu et al. conducted phylogenetic analyses of HCV inTable 3 Reported HCV transmission risk factors associated with diffe
HCV genotype Blood transfusion, n (%) Surgery,n (%)
1 (n = 702) 265 (37.75) 262 (37.32)
2 (n = 193) 67 (34.72) 64 (33.16)
3 (n = 50) 8 (16.0)a,b 11 (22.0)a
6 (n = 25) 4 (16.0) 6 (24.0)
aGenotype 1 vs. genotype 3: p < 0.05; bgenotype 2 vs. genotype 3: p < 0.05; cgenoty
3 vs. genotype 4: p < 0.05; fgenotype 1 vs. genotype 4: p < 0.05; IDU, intravenous drsouthern China, and revealed the constantly changing pat-
tern of HCV genotypes in China over time [8]. Rao et al.
reported the HCV genotype distribution in chronic hepa-
titis C patients in the Han ethnic population in China
[10]. To provide a clear picture of the nationwide geno-
type distribution of HCV infection, we selected 23 hospi-
tals from six geographic regions of China and enrolled
1012 naive chronic hepatitis C patients. Overall, the pre-
dominance of subtype 1b, followed by 2a, is in concord-
ance with previous studies performed in different regions
and different populations of China [7–10]. Previously, Lu
et al. reported that genotype 6 accounted for 12.94 % of
HCV infections in China [6]. In contrast, however, the
frequency of this genotype in our study was much
lower (2.58 %). We consider that this difference is due
to patient selection, since more patients were enrolled
from southern China in the Lu et al. study, where geno-
type 6 HCV infection is more prevalent than in other
areas of China [8, 10, 14, 15].
Previous studies characterized genotypes 3 and 6 of
HCV as geographically limited to western and southern
China [6, 14, 15]. Recently Rong et al. reported that
genotype 6a has spread from southern China and is now
present nationwide [16]. The results were confirmed in
this study, since we also found subtype 6a infection in
eastern China, northern China, and northeastern China.
However in this study, genotype 6n was also found in
eastern China. Gentoypes 3a and 3b were found in
northeastern, northern, and eastern China. Taken together,
these results reflected that genotypes 3 and 6 have already
spread nationwide, possibly due to economic reasons.
The greatest diversity of HCV subtypes was found in
eastern China, which may be explained by the rapid eco-
nomic development and high population mobility. Only
2 HCV subtypes were found in patients from central
China, which may be related to the relatively small sam-
ple size and low population mobility in this area.
Our results support a correlation between HCV sub-
types and routes of HCV transmission. More than 30 %
of individuals with HCV subtypes 1b and 2a had a self-
reported history of each blood transfusion and surgery;
this was significantly higher than reports from genotype
3 patients. Among patients with a history of blood trans-
fusion, 86.3 % (297/344) received blood before 1992; inrent HCV genotypes
Invasive Procedure, n (%) IDU, n (%) Family history, n (%)
105 (14.96) 22 (3.13) 13 (1.85)
43 (22.28)c 2 (1.03) 3 (1.55)
11 (22.0) 10 (20.0)a,b 0 (0)
1 (4.0)d,e 5 (20.0)d,f 0 (0)
pe 1 vs. genotype 2: p < 0.05; dgenotype 2 vs. genotype 4: p < 0.05; egenotype
ug use
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and blood products for HCV. These results indicate that
subtypes 1b and 2a are more related to blood transfusion
than genotype 3, and also partially explain why subtype
1b and 2a patients are generally older than genotype 3
patients when first diagnosed. Previous studies from
other countries and regions reported that genotypes 6
and 3 are more frequent among IDU patients than in
the general population [17–19]. Our current results are
consistent with these reports, since more Chinese geno-
type 3 and 6 patients had a history of IDU when compared
to genotype 1b and 2a patients. Although genotype 3 and
6 patients are younger than genotype 1b and 2a patients,
IDU hepatitis C patients have higher risk of co-infection
of HIV and HBV, which may accelerate disease progres-
sion. Therefore, special attention should be paid to these
IDU patients.
Conclusion
This study reveals the current HCV genotype and sub-
type distribution among Chinese chronic hepatitis C pa-
tients. At least four genotypes and seven subtypes were
prevalent nationally. The distribution of HCV genotypes
vary by geographic region, while subtypes 1b and 2a re-
main the most prevalent in China. Genotype 3 and 6
HCV infections are no longer restricted to southern and
western China, but are now nationwide, and this altered
distribution appears closely related to IDU.
Materials and methods
Study population
From June 2011 to March 2012, treatment-naive chronic
hepatitis C patients were randomly enrolled from 23 hos-
pitals in China. HCV infection had been confirmed (anti-
HCV antibody and HCV RNA-positive) within 90 days
prior to enrollment. Patients who had received anti-HCV
therapy were excluded; no other exclusion criteria were
applied. Patients were from 24 administrative units, which
covered northeast China (Heilongjiang Province, Jilin
Province, and Liaoning Province), northern China (Beijing
Municipality, Tianjin Municipality, Hebei Province, Inner
Mongolia Autonomous Region, and Shanxi Province),
central China (Henan Province, Hubei Province, Hunan
Province), eastern China (Anhui Province, Zhejiang Prov-
ince, Shanghai Municipality, Jiangsu Province, Shandong
Province, Jiangxi Province, and Fujian province), southern
China (Guangdong Province), and western China (Sichuan
Province, Xinjiang Uygur Autonomous Region, Qinghai
Province, Shaanxi Province, and Gansu Province). Demo-
graphic information (gender, age, birthplace, etc.) and
transmission risk factors (including history of blood trans-
fusions, surgeries, invasive procedures (dental work, tattoo-
ing/piercing, etc.), or intravenous drug use (IDU), and
family clustering of HCV infections) were collected fromeach patient with a face-to-face interview based on a ques-
tionnaire. Serum specimens were collected and sent to the
central laboratory of the Beijing Ditan Hospital for study.
This study was approved by the ethics committee of
Beijing Ditan Hospital of Capital Medical University.
Written informed consent was obtained from all subjects
when enrolled.HCV RNA extraction and reverse-transcription polymerase
chain reaction (RT-PCR)
HCV RNA was extracted from 140 μL of each serum sam-
ple using the QIAmp Viral RNA Mini kit (Qiagen China
Co., Ltd, Shanghai, China), followed by one-step RT-PCR
assays with the One Step RNA PCR kit (AMV; TaKaRa
Biotechnology Co. Ltd., Dalian, China). Outer sense and
antisense primers derived from the NS5B and CORE/E1
region of the HCV genome were used for RT-PCR as de-
scribed previously [20]. Nested PCR was performed using
10 μL of the RT-PCR product using GoTaq Colorless
Master Mix (Promega Biotech Co Ltd., Beijing, China),
and primers as specified previously [20]. The final PCR
products were confirmed by 2 % agarose gel electrophor-
esis and visualization with ethidium bromide staining.
Amplified products were sent to Beijing Centre for Phys-
ical and Chemical Analysis for sequencing with both the
sense and antisense inner primers.HCV genotyping and phylogenetic analyses
The sequences of the core/E1 and NS5B regions were
aligned and edited with reference sequences of each sub-
type using the CLUSTALW multiple alignment program
in BioEdit software [21]. HCV subtype reference se-
quences were derived from the Los Alamos HCV database
[22]. Phylogenetic analysis was performed using the
neighbor-joining method using MEGA 4, and the Kimura
two-parameter method was chosen to evaluate genetic
distances [23]. The reliability of the phylogenetic cluster-
ing was evaluated using bootstrap analysis with 1000 repli-
cates. A patient’s HCV subtype was determined when it
was included in a defined cluster with given reference
strains and with a bootstrap value above 70.Statistical analysis
Statistical data analyses were performed with SPSS 13.0.
The continuous data were expressed as the mean ± stand-
ard deviation (SD) or as otherwise stated, and categorical
variables in absolute numbers and percentages. The stu-
dent’s t-test was used to compare the mean ages between
patients infected with different HCV subtypes. The Pear-
son Chi-Square test was used to compare the ratio of risk
factors between different genotypes. p values < 0.05 were
considered statistically significant.
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Beijing Ditan Hospital, Capital Medical University.Additional files
Additional file 1: Figure S1. Subtype 1a phylogeny estimated from
NS5B region sequences (H77 positions: 8244–8713). Subtype 1b sequence
AB049088 and subtype 2a sequence D00944 were used as outgroups.
Black circles are Chinese isolates reported in other studies and white
circles label reference sequences from outside China. Sequences without
a circle were from this study.
Additional file 2: Figure S2. Subtype 1b phylogeny estimated from
NS5B region sequences (H77 positions: 8244–8713). Subtype 1a sequence
NC 004102 and subtype 2a sequence D00944 were used as outgroups.
Black circles are Chinese isolates reported in other studies and white
circles label reference sequences from outside China. Sequences without
a circle were from this study. Black triangles represent the locations of
clusters, which is not showed in detail for shortage of space.
Additional file 3: Figure S3. Subtype 2a phylogeny estimated from
NS5B region sequences (H77 positions: 8244–8713). Subtype 1a sequence
NC 004102 and subtype 2b sequence AB559564 were used as outgroups.
Black circles are Chinese isolates reported in other studies and white
circles label reference sequences from outside China. Sequences without
a circle were from this study. Black triangle represents the location of the
cluster, which is not showed in detail for shortage of space.
Additional file 4: Figure S4. Subtype 3a phylogeny estimated from
NS5B region sequences (H77 positions: 8244–8713). Subtype 1a sequence
NC 004102 and subtype 3b sequence D49374 were used as outgroups.
Black circles are Chinese isolates reported in other studies and white
circles label reference sequences from outside China. Sequences without
a circle were from this study.
Additional file 5: Figure S5. Subtype 3b phylogeny estimated from
NS5B region sequences (H77 positions: 8244–8713). Subtype 1a sequence
NC 004102 and subtype 3a sequence EU710463 were used as outgroups.
Black circles are Chinese isolates reported in other studies and white
circles label reference sequences from outside China. Sequences without
a circle were from this study.
Additional file 6: Figure S6. Subtype 6a phylogeny estimated from
CORE/E1 region sequences (H77 positions: 834–1318). Subtype 1a
sequence NC 004102 and subtype 6b sequence D37841 were used as
outgroups. Black circles are Chinese isolates reported in other studies and
white circles label reference sequences from outside China. Sequences
without a circle were from this study.
Additional file 7: Figure S7. Subtype 6n phylogeny estimated from
CORE/E1 region sequences (H77 positions: 834–1318). Subtype 1a
sequence NC 004102 and subtype 6a sequence Y12083 were used as
outgroups. Black circles are Chinese isolates reported in other studies and
white circles label reference sequences from outside China. Sequences
without a circle were from this study.Abbreviations
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